Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: A national cross-sectional survey

Swiss Medical Weekly

Volumn 141, Issue JULY, 2011, Pages

  Gerber, Philipp Andreas ^a   Spirk, David ^b   Brändle, Michael ^c   Thoenes, Martin ^b,d   Lehmann, Roger ^a   Keller, Ulrich ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Sanofi Aventis (Suisse) Sa   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Endocrinological Practice   (Switzerland)

Author keywords

Anti hyperglycaemic medication; Body weight; Glycaemic control; Insulin; Type 2 diabetes

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; CULTURAL FACTOR; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GERMANY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HUMAN; INSULIN TREATMENT; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; RISK ASSESSMENT; SWITZERLAND; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; BLOOD; BLOOD PRESSURE; DRUG COMBINATION; ETHNOLOGY; HEALTH SURVEY; METABOLISM; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDY;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SURVEYS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; SWITZERLAND; TRIGLYCERIDES;

EID: 80052222342     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13218     Document Type: Article

References (17)

1. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413-20.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
4. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72. (Pubitemid 351831357)
5. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 Aug 5.
6. Standards of medical care in diabetes - 2009. Diabetes care. 2009;32(Suppl 1):S13-61.
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52(1):17-30.
8. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes, obesity & metabolism. 2008;10(Suppl 1):8-15.
9. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes care. 2008;31(1):81-6.
10. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia. 2002;45(7):S23-8.
11. Melander A, Folino-Gallo P, Walley T, Schwabe U, Groop PH, Klaukka T, et al. Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. Diabetologia. 2006;49(9):2024-9. (Pubitemid 44168468)
12. Philippe J, Brändle M, Carrel J, Diem P, Keller U, Kuntschen F, et al. Massnahmen zur Blutzuckerkontrolle bei Patienten mit Typ-2-Diabetes- mellitus. Schweiz Med Forum. 2009;9(3):50-5.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
14. Allemann S, Saner C, Zwahlen M, Christ ER, Diem P, Stettler C. Long-term cardiovascular and non-cardiovascular mortality in women and men with type 1 and type 2 diabetes mellitus: a 30-year follow-up in Switzerland. Swiss Med Wkly. 2009;139(39-40):576-83.
15. Brandle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly. 2009;139(11-12):173-84.
16. Rumawas ME, Meigs JB, Dwyer JT, McKeown NM, Jacques PF. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. Am J Clin Nutr. 2009;90(6):1608-14.
17. Eichholzer M, Bovey F, Jordan P, Probst-Hensch N, Stoffel-Kurt N. Data on overweight and nutrition in the 2007 Swiss Health Survey. Praxis. 2010;99(1):17-25.